BSE · 544169
Amkay Products Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹40 Cr with net profit ₹3 Cr — a 8.41% net margin, versus 8.14% the period before.
Shareholding
As of 2026-06-30
- Promoter73.44%
- Public26.56%
393 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.09× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #41 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,22,166 Cr | 65.86 | 12.9 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹98,512 Cr | 99.07 | 9.17 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹74,771 Cr | 68.08 | 7.56 | 10.53% | 11.41% |
| Aster DM Healthcare Ltd. | ₹42,224 Cr | 4.5 | 9.99 | 8.48% | 8.36% |
| Narayana Hrudayalaya Ltd. | ₹38,691 Cr | 43.75 | 8.53 | 17.76% | 10.2% |
| Global Health Limited | ₹33,209 Cr | 66.86 | 8.38 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,495 Cr | 66.52 | 14.01 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹26,830 Cr | 42.52 | 10.7 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹15,520 Cr | 67.11 | 5 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹13,950 Cr | 169.28 | 6.89 | 6.58% | 6.4% |
| Amkay Products Limited(this company) | ₹42 Cr | 17.97 | 1.57 | 8.76% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAmkay Products Limited is listed on the Indian markets. The company reported a market capitalization of Rs 43 Cr. Its EPS stands at Rs 2.67, with a Book Value of Rs 30.47. The company's revenue was Rs 39.71 Cr.
Positives
- +The Debt-to-Equity ratio is low at 0.24, indicating sound financial leverage.
- +Promoter holding is high at 73.4378% as of June 30, 2026.
- +There are no pledged shares by promoters, with promoter pledge at 0%.
Negatives
- −The company's profit margin is 0%, indicating no profitability.
- −The Return on Equity (ROE) is relatively low at 8.76%.
- −Return on Capital Employed (ROCE) is 11.99%, suggesting moderate efficiency in capital utilization.
- −The company has not disclosed any quarterly results.
Financial Performance
Amkay Products Limited's revenue for the fiscal year ending March 2025 was Rs 39.7084 Cr, with a Net Profit of Rs 3.3385 Cr. This marks an increase from the previous year, where revenue was Rs 32.3183 Cr and net profit was Rs 2.63 Cr for March 2024. In earlier periods, revenue was Rs 28.3289 Cr in Mar 2023, Rs 36.7945 Cr in Mar 2022, and Rs 40.7174 Cr in Mar 2021.
Profitability & Returns
The company's Return on Equity (ROE) is 8.76%, and Return on Capital Employed (ROCE) is 11.99%. The Profit Margin is 0%. The Earnings Per Share (EPS) for the fiscal year ending March 2025 was Rs 3.96, an increase from Rs 4.13 in March 2024. In previous years, EPS was Rs 2.43 in Mar 2023, Rs 2.31 in Mar 2022, and Rs 4.91 in Mar 2021.
Balance Sheet
The Debt to Equity ratio of Amkay Products Limited is 0.24, indicating a low level of debt relative to equity. The Book Value per share is Rs 30.47.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Amkay Products Limited is 73.4378%. Public shareholding stands at 26.5622%. There is no promoter pledge. The number of shareholders is 393.
Shareholding History
Promoter holding has shown consistency at 73.4378% from March 2023 to June 2026. Public shareholding has fluctuated, from 0.112% in February 2024 to 26.5622% in March 2025 and June 2026. Institutional holding (DII + FII) has also varied, from 0% in February 2024 to 11.7149% in March 2024, and 0% in June 2026.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.